Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, 81% of patients with chronic migraine in Glasgow continued using erenumab for significant headache reduction at three months, suggesting a high response rate.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This study reviewed various treatments for migraines and found that both classic medications, such as triptans and beta-blockers, and newer options like CGRP inhibitors, are effective, while non-pharmacological approaches provide moderate relief and are highly effective preventively, though accessibility can be an issue.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.